STAT July 24, 2024
Elaine Chen

Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing the biotech closer to joining the highly competitive GLP-1 drug market.

The San Diego-based biotech previously said it was anticipating to start a Phase 2b trial of the therapy, VK2735, after getting positive results from a Phase 2 study. But after receiving feedback from regulators, the company now plans to advance directly into a Phase 3 trial, the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech
Related Articles:
First Comprehensive Review of SMA Drugs Offers Long-Term Insights, Outcome Gaps
Health Rounds: Next Generation Lilly Weight-loss Drug Shows Added Heart, Liver Benefits
Drugmaker might be 1st healthcare company to top $1 trillion valuation
Pharma Pulse 9/5/24: Legal Advice for DSCSA Compliance Teams, Pharmacy Students Discuss Learning Through Social Media Platforms & more
RNA treatment shows promise for enhancing memory and reducing anxiety

Share This Article